Biotech: Generics Win a Round

If a health-care reform package makes it through Congress this year, it's safe to assume it will include a defined regulatory pathway for generic biotechnology drugs. But there's one major question for which generic and brand-name drugmakers can't find a mutually agreeable answer: How long should a biotech company own the data that reveal how it created a drug?

To continue reading this article you must be a Bloomberg Professional Service Subscriber.